Should ticagrelor (Brilinta) be held until the international normalized ratio (INR) reaches the therapeutic range?

Should Brilinta Be Held Until INR is Therapeutic?

No, Brilinta (ticagrelor) should NOT be held until INR is therapeutic—instead, both agents should be initiated together when triple therapy is indicated, with the duration of triple therapy minimized to reduce bleeding risk.

Clinical Context and Rationale

When patients require both antiplatelet therapy (Brilinta) and oral anticoagulation (warfarin), the decision depends on the clinical indication:

For Patients with ACS Requiring Anticoagulation

Triple therapy (warfarin + aspirin + ticagrelor) should be initiated simultaneously when there is a compelling indication for oral anticoagulation (e.g., atrial fibrillation, mechanical valve, left ventricular thrombus) 1. The key principle is minimizing the duration of triple therapy rather than sequencing the medications 1, 2.

• Duration of triple therapy should be limited to maximum 6 months or discontinued after hospital discharge, based on individualized ischemic versus bleeding risk assessment 2
• After the initial high-risk period, transition to warfarin plus single antiplatelet therapy (typically aspirin) 3
• Target INR of 2.0-2.5 may be reasonable (rather than 2.0-3.0) when combining with dual antiplatelet therapy to reduce bleeding risk 1

Specific Clinical Scenarios

For anterior MI with LV thrombus requiring stenting:

• Triple therapy (warfarin INR 2.0-3.0 + aspirin + clopidogrel) for 3-6 months if drug-eluting stent placed 3
• Note: Guidelines specifically mention clopidogrel rather than ticagrelor for this triple therapy scenario, as ticagrelor use with anticoagulation is not recommended in the triple therapy setting 2

For patients with atrial fibrillation and ACS:

• The 2014 AHA/ACC guidelines emphasize that triple therapy duration should be minimized to reduce bleeding complications 1
• Proton pump inhibitors should be prescribed to all patients on triple therapy with history of GI bleeding, and are reasonable for those without such history 1

Critical Safety Considerations

Bleeding Risk

The combination of oral antiplatelet therapy and oral anticoagulation significantly increases bleeding risk 1:

• Single antiplatelet + anticoagulation: 4-6% bleeding risk
• Dual antiplatelet + anticoagulation (triple therapy): 10-14% bleeding risk
• Risk is duration-dependent 1

Ticagrelor-Specific Concerns

The FDA label warns that drugs inhibiting platelet function including Brilinta increase bleeding risk 4. The 2017 ESC guidelines explicitly state that ticagrelor or prasugrel use is not recommended in the triple therapy setting 2, suggesting clopidogrel is preferred when triple therapy is necessary.

Practical Management Algorithm

1. Assess indication for anticoagulation: Is it compelling and cannot be deferred?
2. If anticoagulation is mandatory:
   • Start warfarin and ticagrelor simultaneously (do not delay either)
   • Add aspirin 75-100 mg daily 1
   • Consider switching ticagrelor to clopidogrel for triple therapy based on ESC guidance 2
3. Minimize triple therapy duration: Target ≤6 months maximum 2
4. Add PPI prophylaxis for GI protection 1
5. Transition strategy: After initial period, continue warfarin + single antiplatelet (typically aspirin)

Common Pitfalls to Avoid

• Do not delay ticagrelor waiting for therapeutic INR—this increases thrombotic risk without reducing bleeding risk, as warfarin takes 4-8 days for full effect 5
• Do not continue triple therapy beyond necessary duration—bleeding risk accumulates over time 1
• Do not use ticagrelor if clopidogrel is an option for triple therapy—ESC guidelines specifically recommend against ticagrelor/prasugrel in this setting 2
• Do not forget PPI prophylaxis—this is a Class I recommendation for patients with GI bleeding history 1

The evidence consistently supports simultaneous initiation with careful attention to minimizing exposure duration rather than sequential therapy.